Clinical trials: Postmenopause
Postmenopause
A Long-Term Study to Evaluate the Safety of Asoprisnil and Estrogen Administration to Postmenopausal Women
The objective of this study is to determine the long-term safety of asoprisnil 10 mg when administered to postmenopausal women with Premarin® 0.625 mg
- Trial name
- NCT00152295
- Testing
- Asoprisnil/Premarin
- Volunteers
- 18 people
- Sponsor
- Abbott
Postmenopause
Endometrial Safety Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination
The purpose of this study is to demonstrate endometrial safety of continuous combined 0.5 mg estradiol and 2.5 mg dydrogesterone.
- Trial name
- NCT00160316
- Testing
- 0.5 Mg Estradiol and 2.5 Mg Dydrogesterone
- Where
- 22 sites in Croatia, Poland and 2 more
- Volunteers
- 454 people
- Sponsor
- Solvay Pharmaceuticals
Postmenopause
Vasomotoric Symptoms Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination
To demonstrate efficacy of continuous combined 0.5 mg estradiol and 2.5 mg dydrogesterone versus placebo in the treatment of vasomotor symptoms after a treatment period of 3 months and to investigate the bleeding pattern over a…
- Trial name
- NCT00251082
- Testing
- continuous combined estradiol and dydrogesterone
- Where
- 18 sites in Croatia, France and 3 more
- Volunteers
- 391 people
- Sponsor
- Solvay Pharmaceuticals
Postmenopause
Study Evaluating Bazedoxifene/CE in Postmenopausal Women
The purpose of this clinical trial is to study the blood levels of a drug (conjugated estrogens) in the body from one dosage form compared to another.
- Trial name
- NCT00550433
- Testing
- Bazedoxifene/Conjugated Estrogens
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Postmenopause, Osteoporosis
Study Evaluating the Safety and Efficacy of Bazedoxifene in Postmenopausal Asian Women
The purpose of this study is to evaluate the effect of 20 mg of bazedoxifene in comparison to placebo on bone mineral density after 6 months of therapy in a population of postmenopausal Asian women.
- Trial name
- NCT00384072
- Testing
- bazedoxifene BZA-20
- Where
- 20 sites in China, South Korea and 1 more
- Volunteers
- 500 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Postmenopause
Study Of Pharmacokinetic (PK) Profile of Bazedoxifene (BZA) in 2 BZA/Conjugated Estrogen Forms
The purpose of the study is to understand how bazedoxifene is absorbed in the body when it is given in combination with 2 different formulations of conjugated estrogens.
- Trial name
- NCT00479778
- Testing
- Bazedoxifene/conjugated estrogens
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Postmenopause
Tolerability & Safety of Premarin Vaginal Cream in Indian Postmenopausal Women
This post-marketing study will provide local safety and tolerance data on the use of Premarin® vaginal cream.
- Trial name
- NCT00484107
- Testing
- Conjugated Estrogen Cream (Premarin®)
- Volunteers
- 200 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Postmenopause
Study Evaluating Estradiol/Trimegestone in Vasomotor Symptoms (VMS) in Post-Menopausal Women.
The purpose of this study is to evaluate vasomotor symptoms (VMS) control of the continuous regimen 17 b estradiol/trimegestone combination.
- Trial name
- NCT00195455
- Testing
- Trimegestone, 17b Estradiol
- Where
- 6 sites in Mexico
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Postmenopause
Bioequivalence Study of 3 New Formulations of Premarin/MPA Compared With Premarin/MPA (Prempro)
To evaluate three new investigational tablet formulations of the Food and Drug Administration (FDA) approved medication Prempro™, Premarin combined with medroxyprogesterone acetate (MPA).
- Trial name
- NCT00472927
- Testing
- Premarin/MPA 0.45 mg/1.5 mg
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Postmenopausal Osteoporosis, Postmenopause
Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation.
This study will compare the bioequivalence of two new investigational combination formulations of Premarin and medroxyprogesterone acetate (MPA) with a currently marketed formulation of Premarin and medroxyprogesterone, Prempro™.
- Trial name
- NCT00381251
- Testing
- Formulations A and B of Premarin/MPA 0.45 mg/0.5 mg and PREMPRO0.45 mg/0.5 mg
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Postmenopause
Study Comparing Four New Formulations for Premarin in Healthy Postmenopausal Women
The purpose of this study is to determine bioequivalence and bioavailability of four different Premarin/MPA test formulations versus the current formulation for Prempro.
- Trial name
- NCT00380887
- Testing
- Premarin
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Postmenopause
Study Assessing the Effects on Endometrium and Breast of Isoflavone in Post Menopausal Women
The main objective of this study is to determine the effects on the endometrium and breast of 70 mg daily dose of isoflavones.
- Trial name
- NCT00235924
- Testing
- soy isoflavone
- Volunteers
- 300 people
- Sponsor
- Laboratoires Arkopharma